Technion Research & Development Foundation Ltd

Other

Teva Pharmaceutical Industries Limited

Tel Hashomer Medical Research Infrastructure and Services Ltd.

Adicet Therapeutics, Inc.

Adicet Bio, Inc.

Yoram Reiter

Cyril Cohen

Galit Denkberg

Ilan Beer

Keren Sinik

Yael Teboul (Elbaz)

Yael Shperber (Sery)

Reut Erel Segal

Mira Peled Kamar

Ravit Oren

Dror Shmuel Alishekevitz

Kfir Oved

Maya Haus-Cohen

Roy Noy

Avital Lev

Aya Jakobovits

Orit Foord

Eran Eden

Uri Sivan

Eynav Klechevsky

Daulet Kadyl Satpayev

Henricus Renerus Jacobus Mattheus Hoogenboom

Rony Dahan

Martin Akerman

Michal Besser

Oryan Makler

Arbel Artzy-Schnirman

Yael Shperber

Yael Teboul

Affinity binding entities having TCRL binding domain and methods of their use are provided. More specifically these compositions bind HLA-A2/WT1+, HLA-A2/MAGE-A4, HLA-A2/MAGE-A9, HLA-A2/PAP or HLA-A2/TyrD+ cells and as such can be used in diagnostics and therapy.

Affinity entities comprising a TCR-like antibody binding domain with high affinity and fine specificity and uses of same

Antibodies capable of binding HLA-A2/Tyrosinase (TyrD) in an HLA restricted manner are provided. Specifically, the antibodies are capable of binding HLA-A2/TyrD369-377 in an HLA restricted manner. Further provided are complementary determining region (CDR) sequences of heavy chain and light chain of antibodies, and methods of using the antibodies for the treatment of cancer.

Antibodies capable of binding HLA-A2/TyrD in an HLA restricted manner and uses thereof

Provided are isolated complexes comprising a major histocompatibility complex (MHC) class II and a type I diabetes-associated GAD autoantigenic peptide, the isolated complex having a structural conformation which enables isolation of a high affinity entity which comprises an antigen binding domain capable of specifically binding to a native conformation of a complex composed of the MHC class II and the type I diabetes-associated GAD autoantigenic peptide; and isolated high affinity entities comprising an antigen binding domain capable of specifically binding the complex, wherein the isolated high affinity entity does not bind to the MHC class II in an absence of the diabetes-associated GAD autoantigenic peptide, wherein the isolated high affinity entity does not bind to the diabetes-associated GAD autoantigenic peptide in an absence of the MHC class II; and methods and kits using same for diagnostic and therapeutic purposes.

Isolated high affinity entities with T-cell receptor like specificity towards native complexes of MHC class II and glutamic acid decarboxylase (GAD) autoantigenic peptides

A composition-of-matter comprising an antibody or antibody fragment including an antigen-binding region capable of specifically binding an antigen-presenting portion of a complex composed of a human antigen-presenting molecule and an antigen derived from a pathogen is disclosed.

Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof

Antigen-presenting complex-binding compositions and uses thereof

Provided are antibodies comprising an antigen recognition domain capable of binding an MHC molecule being complexed with a human immunodeficiency virus (HIV) peptide, wherein the antibody does not bind the MHC molecule in an absence of the complexed peptide, and wherein the antibody does not bind the peptide in an absence of the MHC molecule. Also provided are methods of using same for diagnosing HIV infection and treating AIDS.

Anti human immunodeficiency antibodies and uses thereof

A method of determining responsiveness to cancer treatment is disclosed. The method comprises analyzing a frequency of tumor infiltrating lymphocytes (TILs) having a CD8CD28CD152signature in a sample of the subject, wherein a frequency of TILs having the CD8CD28CD152signature above a predetermined level is indicative of a positive responsiveness to cancer treatment. Other signatures reflecting responsiveness to cancer treatment are also disclosed. In addition, methods of treating cancer based on these signatures are also disclosed.

Method of predicting responsiveness to autologous adoptive cell transfer therapy

An immuno-molecule which comprises a soluble human MHC class I effector domain; and an antibody targeting domain which is linked to the soluble human MHC class I effector domain, methods of making same and uses thereof.

Immuno-molecules containing viral proteins, compositions thereof and methods of using

Anti CMV antibodies are provided. Thus an antibody of the present invention comprises an antigen recognition domain capable of binding an MHC molecule being complexed with a cytomegalovirus (CMV) pp65 or pp64 peptide, wherein the antibody does not bind said MHC molecule in an absence of said complexed peptide, and wherein the antibody does not bind said peptide in an absence of said MHC molecule. Also provided are methods of using the antibodies.

Antibodies and their uses for diagnosis and treatment of cytomegalovirus infection and associated diseases

Antibodies are provided. For as example, an antibody capable of binding an artificial receptor which comprises a hydroquinone monolayer and is incapable of binding the artificial receptor when comprising a benzoquinone monolayer. Also provided are methods and systems using same for control delivery of a molecule-of-interest into a tissue.

Artificial receptors

This invention provides fusion proteins comprising consecutive amino acids which beginning at the amino terminus of the protein correspond to consecutive amino acids present in (i) a cytomegalovirus human MHC-restricted peptide, (ii) a first peptide linker, (iii) a human &#x3b2;-2 microglobulin, (iv) a second peptide linker, (v) a HLA-A2 chain of a human MHC class I molecule, (vi) a third peptide linker, (vii) a variable region from a heavy chain of a scFv fragment of an antibody, and (viii) a variable region from a light chain of such scFv fragment, wherein the consecutive amino acids which correspond to (vii) and (viii) are bound together directly by a peptide bond or by consecutive amino acids which correspond to a fourth peptide linker, wherein the antibody from which the scFv fragment is derived specifically binds to mesothelin. This invention provides nucleic acid constructs encoding same, processes for producing same, compositions, and uses thereof.

Fusion proteins, uses thereof and processes for producing same

Disclosed are protein ligands comprising an immunoglobulin heavy chain variable (VH) domain and an immunoglobulin light chain variable (VL) domain, wherein the proteins bind a complex comprising an MHC and a peptide, do not substantially bind the MHC in the absence of the bound peptide, and do not substantially bind the peptide in the absence of the MHC, and the peptide is a peptide fragment of gp100, MUC1, TAX, or hTERT. Also disclosed are methods of using and identifying such ligands.

MHC-peptide complex binding ligands

Growing community of inventors

Haifa, Israel

Yoram Reiter